Comparative Pharmacology
Head-to-head clinical analysis: GLYCORT versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCORT versus LUSEDRA.
GLYCORT vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
5 mg orally once daily.
None Documented
None Documented
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic